Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Non-Current Liabilities (2018 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 12 years of Other Non-Current Liabilities data on record, last reported at $25.0 million in Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities rose 107.21% year-over-year to $25.0 million; the TTM value through May 2025 reached $25.0 million, up 107.21%, while the annual FY2025 figure was $25.0 million, 107.21% up from the prior year.
  • Other Non-Current Liabilities reached $25.0 million in Q2 2025 per LFCR's latest filing, up from $23.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $64.9 million in Q2 2023 and bottomed at $183000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 5 years is $13.1 million, with a median of $3.3 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 93.38% in 2022, then skyrocketed 34057.89% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.9 million in 2021, then plummeted by 89.6% to $201000.0 in 2022, then decreased by 8.96% to $183000.0 in 2023, then skyrocketed by 2715.85% to $5.2 million in 2024, then skyrocketed by 384.98% to $25.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $25.0 million in Q2 2025, $23.9 million in Q1 2025, and $5.2 million in Q4 2024.